The resourcefulness of the industry is clearly evident in the number of product approvals and products that are in late stages of clinical development. Two-thirds of these products are being developed to meet the needs of patient and physicians in diseases that represent underserved or unmet medica...(Full transcript available to logged in subscribers.).
Register & Subscribe
Login
